Literature DB >> 9831907

Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor.

J McDonnell1, M L Latif, E S Rees, N J Bevan, S J Hill.   

Abstract

1. The beta2-agonist salmeterol is a potent relaxant of airway smooth muscle with a long duration of action. Previous studies of cyclic AMP accumulation, however, have indicated that salmeterol is a low efficacy beta2-agonist when compared to isoprenaline. Here we have compared the properties of salmeterol and isoprenaline as stimulants of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor to different levels (50 and 310 fmol mg protein(-1)). 2. Gene transcription was monitored using a secreted placental alkaline phosphate (SPAP) reporter gene under the transcriptional control of six cyclic AMP response element (CRE) sequences. 3. In the lower expressing cells (CHO-beta2/6), salmeterol produced a maximal cyclic AMP response that was only 22% that of that obtained with isoprenaline. In contrast in the higher expressing cells (CHO-beta2/ 4), the two maxima were of similar magnitude. 4. Salmeterol was a more potent stimulant of gene transcription, producing the same maximal response as isoprenaline in both cell lines. Furthermore, in the CHO-beta2/4 cells, Salmeterol was 50 fold more potent as a stimulant of SPAP secretion than of cyclic AMP accumulation. In contrast, isoprenaline was 24 fold less sensitive as a stimulant of SPAP secretion than of cyclic AMP accumulation. In the presence of serum (10%), the effects of both salmeterol and isoprenaline on gene transcription were augmented. 5. These data suggest that the low efficacy and/or long duration of action of salmeterol, favours a potent stimulation of gene transcription when compared to more efficacious but shorter-lived agonists such as isoprenaline.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831907      PMCID: PMC1571039          DOI: 10.1038/sj.bjp.0702139

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors.

Authors:  H E Hopkinson; M L Latif; S J Hill
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.

Authors:  Stephen J Hill; Christine Williams; Lauren T May
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

Authors:  Steven J Charlton
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

4.  The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria.

Authors:  W Abdel-Razaq; D A Kendall; T E Bates
Journal:  Neurochem Res       Date:  2010-12-01       Impact factor: 3.996

5.  Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways.

Authors:  Dana S Hutchinson; Tore Bengtsson; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells.

Authors:  M G Scott; C Swan; T M Jobson; S Rees; I P Hall
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

7.  Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  An Aplysia Egr homolog is rapidly and persistently regulated by long-term sensitization training.

Authors:  Ashly Cyriac; Geraldine Holmes; Jamie Lass; Dmitry Belchenko; Robert J Calin-Jageman; Irina E Calin-Jageman
Journal:  Neurobiol Learn Mem       Date:  2013-04-06       Impact factor: 2.877

10.  LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A2A Receptor.

Authors:  Vinicius F Carvalho; Tatiana P T Ferreira; Ana C S de Arantes; François Noël; Roberta Tesch; Carlos M R Sant'Anna; Eliezer J L Barreiro; Carlos A M Fraga; Patrícia M Rodrigues E Silva; Marco A Martins
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.